Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves”
or the “Company”), a global medicinal cannabis company, announced
that its Colombian flower is now available to patients in Australia
through a partnership with Australian Natural Therapeutics Group
(“ANTG”), one of the leading medicinal cannabis providers in
Australia. The products are available to medical patients in
Australia under ANTG’s “Global Selects” brand portfolio.
Clever Leaves provides a sustainable, reliable,
and cost-effective supply of pharmaceutical-grade cannabinoids and
active pharmaceutical ingredients from its EU GMP certified
cultivation facility in Colombia to more than 15 countries across
the globe. ANTG’s evolving brand portfolio signifies its commitment
to providing Australian patients with a consistent supply of
medicinal-grade plant medicine. The new ‘Global Selects’ range is
widely available through pharmacy outlets across the country.
“As Australia’s medical market continues to
grow, working with ANTG marks a significant milestone for us. We
are committed to facilitating access to our Colombian flower for
those seeking to enhance their quality of life through medicinal
products cultivated in our country,” said Andrés Fajardo, CEO of
Clever Leaves. “Our working relationship with ANTG has been
exceptional, as a renowned company for its commitment to research,
certified quality standards, and distribution capabilities, all in
line with our goal to produce the highest quality,
cannabinoid-based products for medical patients worldwide.”
In Australia, medical cannabis is used to treat
thousands of patients each year for conditions including anxiety,
inflammation, seizures, and pain management. According to official
data from the Therapeutic Goods Administration (TGA), in 2022 there
were 319,000 reported patients, while in 2021 this number was
150,000.1 Additionally, interest in local clinical research to test
the efficacy of cannabinoid products for numerous medical
conditions is increasing. Current research areas include sleep
apnea, PTSD, cancer, depression, and dementia, among others.
ANTG’s CEO Matt Cantelo said, “Knowing that
Clever Leaves´ Colombian flower is available for patients in
Australia as part of our “Global Selects" portfolio is something
that we are very proud of. Our companies share a strong commitment
to product provenance that ensures quality assurance is at the
forefront of bringing cannabinoid medicine into the world as a
high-value health solution.”
Clever Leaves is the first and only medicinal
cannabis company globally with GMP certifications from the EU,
Colombia, and Brazil. Clever Leaves has the ability to ship
high-quality pharmaceutical-grade products from its world-class
facility in Colombia that meets all regulatory standards throughout
the five continents that recognize GMP standards.
About Clever Leaves Holdings Inc.
Clever Leaves is a global medical cannabis
company. Its operations in Colombia produce EU GMP cannabinoid
active pharmaceutical ingredients (API) and finished products in
flower and extract form to a growing base of B2B customers around
the globe. Clever Leaves aims to disrupt the traditional cannabis
production industry by leveraging environmentally sustainable,
ESG-friendly, industrial-scale and low-cost production methods,
with the world’s most stringent pharmaceutical quality
certifications. Clever Leaves announces material information to the
public through a variety of means, including filings with the U.S.
Securities and Exchange Commission (the “SEC”), press releases,
public conference calls, and its website
(https://cleverleaves.com). Clever Leaves uses these channels, as
well as social media, including its Twitter account
(@clever_leaves), and its LinkedIn page
(https://www.linkedin.com/company/clever-leaves), to communicate
with investors and the public about Clever Leaves, its products,
and other matters. Therefore, Clever Leaves encourages investors,
the media, and others interested in Clever Leaves to review the
information it makes public in these locations, as such information
could be deemed to be material information. Information on or that
can be accessed through Clever Leaves’ websites or these social
media channels is not part of this release, and references to
Clever Leaves’ website addresses and social media channels are
inactive textual references only.
About ANTG
ANTG produces exclusive high-quality cannabinoid
based medicinal treatments that can meet individual patient needs.
We combine a strong research focus with best-in-class cultivation
and extraction methods to develop cannabinoid medicines. Our team
has witnessed first-hand the power of medicinal cannabis in
relieving chronic and debilitating disease symptoms in areas where
traditional treatments lack efficacy and or have significant side
effects. It’s these personal experiences that motivated us to
establish our company in 2015. Our passion for the plant underpins
our focus on putting the needs of patients first – and we believe,
as an independent company, that we are uniquely positioned to
achieve more and be more for the benefit of humanity.
For more information, visit
https://australiannatural.com/about/ and follow ANTG on LinkedIn,
Facebook, and Twitter
FORWARD-LOOKING STATEMENTS
This press release
includes certain statements that are not historical facts but are
forward-looking statements for purposes of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally are
accompanied by words such as “aim,” “anticipate,” “believe,” “can,”
“continue,” “could,” “estimate,” “evolve,” “expect,” “forecast,”
“future,” “guidance,” “intend,” “may,” “opportunity,” “outlook,”
“pipeline,” “plan,” “predict,” “potential,” “projected,” “seek,”
“seem,” “should,” “will,” “would” and similar expressions (or the
negative versions of such words or expressions) that predict or
indicate future events or trends or that are not statements of
historical matters. Such forward-looking statements as well as our
outlook for 2023 are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Important factors that may affect actual results or the
achievability of the Company’s expectations include, but are not
limited to: (i) our ability to continue as a going concern; (ii)
our ability to maintain the listing of our securities on Nasdaq;
(iii) our ability to implement our restructuring initiatives; (iv)
expectations with respect to future operating and financial
performance and growth, including if or when Clever Leaves will
become profitable; (v) Clever Leaves’ ability to execute its
business plans and strategy and to receive regulatory approvals
(including its goals in its five key markets); (vi) Clever Leaves’
ability to capitalize on expected market opportunities, including
the timing and extent to which cannabis is legalized in various
jurisdictions; (vii) global economic and business conditions,
including recent economic sanctions against Russia and their
effects on the global economy; (viii) geopolitical events
(including the ongoing military conflict between Russia and
Ukraine), natural disasters, acts of God and pandemics, including
the economic and operational disruptions and other effects of
COVID-19; (ix) regulatory developments in key markets for the
Company's products, including international regulatory agency
coordination and increased quality standards imposed by certain
health regulatory agencies, and failure to otherwise comply with
laws and regulations; (x) uncertainty with respect to the
requirements applicable to certain cannabis products as well as the
permissibility of sample shipments, and other risks and
uncertainties; (xi) consumer, legislative, and regulatory sentiment
or perception regarding Clever Leaves’ products; (xii) lack of
regulatory approval and market acceptance of Clever Leaves’ new
products which may impede its ability to successfully commercialize
its products; (xiii) the extent to which Clever Leaves’ is able to
monetize its existing THC market quota within Colombia; (xiv)
demand for Clever Leaves’ products and Clever Leaves’ ability to
meet demand for its products and negotiate agreements with existing
and new customers, including the sales agreements identified as a
part of the Company’s 2023 strategic growth objectives; (xv)
developing product enhancements and formulations with commercial
value and appeal; (xvi) product liability claims exposure; (xvii)
lack of a history and experience operating a business on a large
scale and across multiple jurisdictions; (xviii) limited experience
operating as a public company; (xix) changes in currency exchange
rates and interest rates; (xx) weather and agricultural conditions
and their impact on the Company’s cultivation plans, (xxi) Clever
Leaves’ ability to hire and retain skilled personnel in the
jurisdictions where it operates; (xxii) Clever Leaves’ ability to
remediate a material weakness in its internal controls over
financial reporting and to develop and maintain effective internal
and disclosure controls; (xxiii) potential litigation; (xiv) access
to additional financing; and (xxv) completion of our construction
initiatives on time and on budget. The foregoing list of factors is
not exclusive. Additional information concerning certain of these
and other risk factors is contained in Clever Leaves’ most recent
filings with the SEC. All subsequent written and oral
forward-looking statements concerning Clever Leaves and
attributable to Clever Leaves or any person acting on its behalf
are expressly qualified in their entirety by the cautionary
statements above. Readers are cautioned not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. Clever Leaves expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in its expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Clever Leaves Press
Contacts:Maria PetsanasKCSA Strategic
Communications+1-917-692-6673cleverleaves@kcsa.com
Clever Leaves Commercial
Inquiries:Keith KleinCommercial Manager – Australia and
New Zealand+61 475 212 988keith.klein@cleverleaves.com
Clever Leaves Investor
Inquiries:Cody Slach and Jackie KeshnerGateway Investor
Relations+1-949-574-3860CLVR@gatewayir.com
ANTG Press Contacts:Oryana
Angel oryana@inthemediapr.com.au+61 400 602 202
1
https://dashboard-data.health.gov.au/single/?appid=f330a1c6-d805-4c64-a6ef-76a69d32d8b7&sheet=a7cdc199-1658-4c94-87d0-9a3b76c520eb&select=clearall
Clever Leaves (NASDAQ:CLVR)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Clever Leaves (NASDAQ:CLVR)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024